Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
Presentation at the MedInvest Oncology Conference (December 7-10, 2021): Propella Therapeutics Corporate Presentation
Propella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.
Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.
Presentation at the American Society of Clinical Oncology Annual Meeting (June 4, 2021; San Francisco, CA): A Phase 1/2a, open-label, multicenter study of intramuscular abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114)
Propella Therapeutics, Inc. presented “A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)” at the American Society of Clinical Oncology Annual Meeting in San Francisco, CA on June 4, 2021.
Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer
Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.
Press Release: Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer
Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (AD) – Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model
Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA on February 11, 2021.
Presentation (Webinar, February 9, 2021): Capsaicin – The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target
Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.
Presentation at the 13th Annual Pain Therapeutics Summit (September 23, 2019; Washington, DC): A phase 2 double-blind clinical trial (VZU00025) to examine the tolerability, safety and effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on osteoarthritis knee pain (OAKP)
Propella Therapeutics, Inc. presented the results of its completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 13th Annual Pain Therapeutics Summit in Washington, DC on September 23, 2019.
Capsaicin cream 0.025% as Monotherapy for Osteoarthritis: A double-blind study
Treatment of Arthritis with Topical Capsaicin: A Double-Blind Trial